Search Results

Total 48 documents found.

• X. Pipeline Development Activities ■ New compounds ■ Additional indications/new formulations ■ Characteristics of projects ■ Other alliance projects ■ Clinical study protocol summaries ■ Outcome studies Research Activities ■ Main joint research activities 18 19 Development activities ■ New Compounds Development code Drug Class (administration route) Indications Stage In-house / In-license Jpn P-III U.S. P-III In-house EU P-III Insomnia Jpn P-III EU Filed (Mar 07) Alzheimer's sleep / wake disturbance U.S. P-II Circadian rhythm sleep disorder (CRSD) U.S. P-II U.S. P-III EU P-III In-house Jpn P-II U.S. P-III Jpn P-I U.S. P-III EU P-III Jpn P-II U.S. P-II EU P-II U.S. P-II EU P-II Jpn P-I U.S. P-II EU P-II Jpn P-I / II Hypercholesterolemia In-license. (Sucampo) P-III conducted by Sucampo Constipation-predominant Irritable Bowel Syndrome U.S. P-III Severe sepsis In-house Chronic kidney disease (CKD) / cancer-related anemia In-houseHypertension TAK-536 < azilsartan > AF37702 < - > Synthetic,

• FFiinnaanncciiaall RReessuullttss ffoorr FFYY22000066 DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Corporate Communications Dept. TEL: +81-3-3278-2037 FAX: +81-3-3278-2741 http://www.takeda.com/ Financial News http://www.takeda.com/financial/index.html 2006-2010 Medium-Term Management Plan 〜 Growth toward a World-class Pharmaceutical Company with Japanese Origin 〜 1. Enhancement of capability to create new drugs through in-house R&D activities ・ Thorough review of the R&D management scheme and investments focused on the global research infrastructure ・ Building a structure that will enable continued launch of new products from its in-house R&D from fiscal 2011 ・ Enhancement of the R&D pipeline to a level where the company can expect sales of in-house ethical products of 2 trillion yen in fiscal 2015 2. Formulation of a tri-polar marketing function (Japan, USA, Europe) ・ Solidifying market function in each region with self-sustaining and appropriate operatio

• ANNUALREPORT2006 Annual Report 2006 Our Contribution to Financial and Social Responsibility *The contents of this annual report are written based on the information as of FY2005 (April 1, 2005 to March 31, 2006) with some activities in FY2006 being included. This annual report includes forward-looking statements regarding Takeda's plans, prospects, strategies and accomplishments, etc. These prospects are the result of assessment obtained from information currently available, and since the actual performance could be influenced by various risks and uncertainty, it shall be noted that the course of action could differ substantially from those prospects. Factors that could affect future prospects would include, but are not limited to, economic circumstances surrounding Takeda's domain identity, competitive pressures, relevant laws and regulations, change in the status of product development, exchange rate risk and so on. Precautions Regarding Forward-Looking Statements There is a recent tendency that a comprehe

• Takeda Annual Report 200618 PROMOTION OF "TIKARAKOBU" RESEARCH STRATEGY: focus resources, balance risk to drive the pipeline Basic Research Strategy CHALLENGES TO THE BEST PRACTICE TOWARD REALIZING OUR MANAGEMENT MISSION Takeda research and development has created four international strategic products (leuprolelin, lansoprazole, candesartan and pioglitazone), which is an example of our mission to strive toward better health for individuals and progress in medicine. Although drug discovery now faces new and unprecedented challenges, we recognize that it is our mission to continue to further develop superior pharmaceutical products to help people around the world. Therefore, in the 2006-2010 Medium-Term Management Plan, we have committed ourselves to the creation of new drugs by harnessing the collective efforts of our researchers and adopting "World Best Practice." This plan comprises of the following five tasks: 1. Maximization of new drug creation capability for both short term, and mid- and long-term range

• FFiinnaanncciiaall RReessuullttss ffoorr FFYY22000055 DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Corporate Communications Dept. TEL: +81-3-3278-2039 FAX: +81-3-3278-2741 http://www.takeda.com/ Financial News http://www.takeda.com/financial/index.html [Takeda-ism] We, the members of the Takeda Group, pledge to act with integrity at all times, especially when facing difficulties or challenges. "Integrity" refers to our compliance with the highest ethical standards, our fairness and honesty in conducting every activity, and our perseverance in pursuing the ideal forms for our operations and management. Through the demonstration of these qualities, we show our commitment to building trust and confidence in all the people around us, and our determination to continue to expand the business. These empower our progress in our global endeavors to fulfill our mission to "strive toward better health for individuals and progress in medicine by developing superior pharmaceutical products." 2

• IX. Pipeline Development Activities ■ New compounds ■ Additional indications / new formulations ■ Characteristics of projects ■ Other alliance projects ■ Clinical study protocol summaries ■ Outcome studies Research Activities ■ Main joint research activities ■ Recent fruits of Takeda research ■ Notes 【Progress in stage (Oct 2005 - Mar 2006)】Indications or formulations Brand name (country/region) Progress in stage Reduction of the risk of macrovascular events in patients with type 2 diabetes mellitus and pre-existing macrovascular disease Actos (EU) P-III→Filed (Dec 05) Diabetes mellitus < Not decided yet > (U.S., EU) P-II→P-III Obesity < Not decided yet > (Jpn) P-I→P-II Erosive esophagitis and non-erosive gastroesophageal reflux disease < Not decided yet > (Jpn) P-I Chronic idiopathic constipation < AMITIZA TM (U.S.) Filed→ Approval (Jan 06) Combination drug of Actos / Metformin XT < ACTOplus met TM XR> (U.S.) Filed (Mar 06) Paget's disease < Benet > (Jpn) P-II→P-III Alzheimer's sleep / wake

• - 8 - (3) Results of Operations and Financial Position 1. Summary of Annual Results 1) Overview of Results The slow-down in growth of the U.S. market, which accounts for almost 50 percent of the total ethical pharmaceutical market in the world, has continued due to the promotion of less expensive generic drug use and the increasing pressure for price reduction in branded products as a result of strong requests by the federal and state governments and Managed Care, together with the impact of prescription-to-OTC switch drugs. Especially in the peptic ulcer therapeutic area, one of Takeda's main franchises, the market for branded products has shown little growth due to the increasing penetration of generic drugs and RX-to-OTC switches. Medicare Part D (prescription drug benefits for outpatients under the federal insurance plan for the elderly), started in the U.S. in January 2006, is expected to bring quantitative expansion of the market in the short term. However, we cannot be very sure about the future as it

• - 1 - Consolidated Financial Statements for the Fiscal Year Ended March 31, 2006 May 11, 2006 These financial statements have been prepared for reference only in accordance with accounting principles and practices generally accepted in Japan. Takeda Pharmaceutical Company Limited Stock exchange listings: Osaka, Tokyo, Nagoya 1-1, Doshomachi 4-chome (First section of each) Chuo-ku, Osaka 540-8645, Japan Fukuoka, Sapporo URL: http://www.takeda.co.jp/ Code number: 4502 Representative: Yasuchika Hasegawa, President and COO Board of Directors meeting: May 11, 2006 Contact: Toyoji Yoshida, Director Use of U.S. accounting standards: No Tel: +81-6-6204-2060 +81-3-3278-2039 1. Results for Fiscal 2005 (April 1, 2005 - March 31, 2006) (1) Sales and Income All amounts are rounded to the nearest million yen. Net sales ( million) Year-on-year change (%) Operating income ( million) Year-on-year change (%) Ordinary income ( million) Year-on-year change (%) Fiscal 2005 Fiscal 2004 1,212,207 1,122,960 7.9 3.4 402,809 385,278

Pages:[1] [2] [3]